| Objective To observe the safety of zoledronic acid injection (Aclasta) in the treatment of osteoporosis in advanced aged patients (over 80 years old), and to analyze its efficacy. Methods Sixty advanced aged osteoporosis patients, who had creatinine clearance rate (Ccr) ≥30ml/min and obvious ostealgia, were randomly divided into study group and control group (30 patients in each group). Patients in study group were treated with zoledronic acid combined with calcium and vitamin D, while patients in control group were treated with calcium and vitamin D only. The pain score, the quality of life, and bone mineral density (BMD) in both groups were determined before and 12 months after the treatment. Results No significant damage of renal function in study group was observed. And there were no other severe adverse reactions. The changes of pain score in 16 patients met the marked effective standards, and the changes in 10 patients met effective standards. The total effective rate of pain relieving was 86.7% in study group. Whereas, the relevant number in control group was 1 and 3, respectively, and the total effective rate was 13.3%. After the treatment, the quality of life improved obviously. BMD of the lumbar vertebrae (L2-4), the right femoral neck, and the right hip increased significantly compared with that before the treatment. And all these indexes had significant difference compared with those in control group (P<0.01). Conclusion Zoledronic acid is safe and effective in the treatment of osteoporosis in advanced aged patients. |